Stone Summit Wealth LLC Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Stone Summit Wealth LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,886 shares of the company’s stock after selling 69 shares during the quarter. Stone Summit Wealth LLC’s holdings in Johnson & Johnson were worth $562,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth $31,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on JNJ shares. Wells Fargo & Company dropped their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Finally, Leerink Partners reduced their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Down 0.6 %

Shares of JNJ stock opened at $155.23 on Thursday. The stock has a 50 day simple moving average of $147.48 and a 200-day simple moving average of $156.01. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a market cap of $373.73 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.